Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

Cancer

Volumn 115, Issue 16, 2009, Pages 3670-3679

  Higano, Celestia S ^a,g   Schellhammer, Paul F ^b   Small, Eric J ^c   Burch, Patrick A ^d   Nemunaitis, John ^e   Yuh, Lianng ^f   Provost, Nicole ^f   Frohlich, Mark W ^f  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MAYO CLINIC   (United States)

^e BAYLOR UNIVERSITY   (United States)

^f Dendreon   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

Author keywords

APC8015; Immunotherapy; Prostate cancer; Provenge; Sipuleucel T; Vaccine

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ALKALINE PHOSPHATASE; DIPHENHYDRAMINE; INTERCELLULAR ADHESION MOLECULE 1; LACTATE DEHYDROGENASE; PARACETAMOL; PLACEBO; PROVENGE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BONE METASTASIS; CANCER IMMUNOTHERAPY; CEREBROVASCULAR DISEASE; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; DYSPNEA; FATIGUE; FEVER; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARESTHESIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; THORAX PAIN; TREMOR; VOMITING;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CANCER VACCINES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; HUMANS; IMMUNITY, ACTIVE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PLACEBOS; PROSTATIC NEOPLASMS; TIME FACTORS; TISSUE EXTRACTS;

EID: 68549135290     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24429     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Ward JF, Moul JW. Biochemical recurrence after definitive prostate cancer therapy. Pt I: Defining and localizing biochemical recurrence of prostate cancer. Curr Opin Urol. 2005;15:181-186.
3. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321:419-424.
4. Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol. 1993;11:1566-1572.
5. Small EJ, Srinivas S. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer. 1995;76:1428-1434.
6. Schellhammer PF, Venner P, Haas GP, et al. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol. 1997;157:1731-1735.
7. Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol. 1997;15:382-388.
8. Scher HI, Zhang ZF, Nanus D, Kelly WK. Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer. Urology. 1996;47(1A suppl):61-69.
9. Haines AM, Larkin SE, Richardson AP, Stirling RW, Heyderman E. A novel hybridoma antibody (PASE/4LJ) to human prostatic acid phosphatase suitable for immunohistochemistry. Br J Cancer. 1989;60:887-892.
10. Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol. 2002;117:471-477.
11. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol. 2004;4:941-952.
12. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000;18:3894-3903.
13. Burch PA, Breen JK, Buckner JC, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res. 2000;6:2175-2182.
14. Burch PA, Croghan GA, Gastineau DA, et al. Immunotherapy (APC8015, Provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a phase 2 trial. Prostate. 2004;60:197-204.
15. Beinart G, Rini BI, Weinberg V, Small EJ. Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin Prostate Cancer. 2005;4:55-60.
16. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24:3089-3094.
17. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17:3461-3467.
18. Small EJ, Meyer M, Marshall ME, et al. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol. 2000;18:1440-1450.
19. Lee D. Clinical trials of atrasentan in hormone-refractory prostate cancer. Clin Prostate Cancer. 2003;2:84-86.
20. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458-1468.
21. James ND, Borre M, Zonnenberg BA, et al. ZD4054, a potent, specific endothelin A receptor antagonist, improves overall survival in pain-free or mildly symptomatic patients with hormone-resistant prostate cancer (HRPC) and bone metastases. EJC Supplements. 2007;5:3.
22. Kantoff PW, Glode LM, Tannenbaum SI, Billhartz DL, Pitman WG, Schuetz TJ. Randomized, double-blind, vector-controlled study of targeted immunotherapy in patients with hormone-refractory prostate cancer. J Clin Oncol, 2006 ASCO Annu Mtg Proc. 2006;24:2501.
23. Beer TM, Bernstein GT, Corman JM. Randomized trial of active cellular immunotherapy with sipuleucel-T in androgen dependent prostate cancer (ADPC). J Clin Oncol, 2007 ASCO Annu Mtg Proc. 2007;25:5059.